For specific product details please scroll to the bottom of the page!
Chimeric antigen receptor-modified T-cell (CAR-T) therapy is a novel immunotherapy approach that has achieved remarkable success in the treatment of a variety of hematological malignancies. The basis of CAR-T therapy is to make the immune system attack cancer cells. Briefly, patient T cells are isolated and genetically engineered to express a chimeric antigen receptor (CAR) that recognizes specific tumor-associated antigens (TAAs) such as CD19, a cell surface protein that is uniformly and strongly expressed on malignant B cells. Two new FDA-approved CD19-specific drugs, KymriahTM and YescartaTM, demonstrate the importance of TAAs in CAR-T cell therapy research. Utilizing our SAMSTM platform, KACTUS has developed a series of recombinant proteins covering multiple CAR-T cell therapeutic targets, including some difficult-to-express proteins such as CD19 and BCMA. KACTUS provides various types of highly active CAR-T target antigen proteins, including site-directed labeled proteins, fluorescent labeled proteins, biotin-labeled proteins, etc., which can flexibly meet different research and development needs such as CAR-T positive rate detection.
Human FITC Compatible CD19
Use Human CD19-FITC Compatible protein to detect the expression rate of Anti-CD19-CAR positive cells. Non-transfected 293T cells and FITC-labeled protein control were used as negative control.
PE-Labeled Human EGFR VIII
293T-CAR Cells were incubated with PE-Labeled Human EGFR VIII, His Tag and PE-labeled protein control. Non-transfected 293T cells and PE-labeled protein control were used as negative control.
Biotinylated Human MSLN
Anti-MSLN CAR-293T cells were incubated with Biotinylated human MSLN-hFc-Avi Tag. Non-transfected 293T cells and Fc-labeled protein control were used as negative control. SA-FITC was used to evaluate the binding activity of Biotinylated Human MSLN.